Swedish Orphan Biovitrum AB (publ) (SWOBY)
| Market Cap | 16.48B +65.9% |
| Revenue (ttm) | 3.16B +13.5% |
| Net Income | 142.59M -68.4% |
| EPS | 0.41 -68.6% |
| Shares Out | n/a |
| PE Ratio | 115.61 |
| Forward PE | 18.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 369 |
| Open | 24.31 |
| Previous Close | n/a |
| Day's Range | 24.31 - 24.31 |
| 52-Week Range | 13.57 - 29.32 |
| Beta | 0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 16, 2026 |
About SWOBY
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy... [Read more]
Financial Performance
In 2025, SWOBY's revenue was 28.24 billion, an increase of 8.50% compared to the previous year's 26.03 billion. Earnings were 478.00 million, a decrease of -87.70%.
Financial numbers in SEK Financial StatementsNews
Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO
(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initi...
Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma
(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutane...
BioNTech says Sobi's Oelkers will replace Sahin as CEO
German biotech firm BioNTech said on Monday that Sobi's CEO Guido Oelkers will succeed Ugur Sahin as its chief executive.
Swedish Orphan Biovitrum price target raised to SEK 515 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 515 from SEK 490 and keeps a Buy rating on the shares.
Swedish Orphan Biovitrum price target raised to SEK 575 at Berenberg
Berenberg raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 575 from SEK 550 and keeps a Buy rating on the shares.
Biovitrum price target raised to SEK 575 from SEK 550 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 575 from SEK 550 and keeps a Buy rating on the shares. The firm says the…
Swedish Orphan Biovitrum downgraded to Hold from Buy at DNB Carnegie
DNB Carnegie downgraded Swedish Orphan Biovitrum (BIOVF) to Hold from Buy with a SEK 475 price target
Swedish Orphan Biovitrum AB Earnings Call Transcript: Q2 2026
Q2 saw 29% revenue growth and a 35% adjusted EBITA margin, driven by strong performance across all regions and key products like ALTUVOCT, Doptelet, and Gamifant. The outlook for 2026 was raised, with continued pipeline progress and new launches supporting long-term growth.
Swedish Orphan Biovitrum AB Quarterly report: Q2 2026
Swedish Orphan Biovitrum AB has published its Q2 2026 quarterly earnings report on July 16, 2026.
Swedish Orphan Biovitrum AB Slides: Q2 2026
Swedish Orphan Biovitrum AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 16, 2026.
Swedish Orphan Biovitrum Earnings Up In Q2; Guides FY26
(RTTNews) - Swedish Orphan Biovitrum AB (SWOBY, BIOVF, SOBI.ST), on Thursday, reported higher net income in the second quarter of 2026 compared with the previous year.
Canada's Drug Agency Backs EMPAVELI For Rare Kidney Disease
(RTTNews) - Swedish Orphan Biovitrum AB (Sobi) (SWOBY) announced that Canada's Drug Agency (CDA) has issued a positive reimbursement recommendation with conditions for EMPAVELI (pegcetacoplan) in adul...
Swedish Orphan price target raised to SEK 530 from SEK 470 at Barclays
Barclays raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 530 from SEK 470 and keeps an Overweight rating on the shares.
Swedish Orphan Biovitrum downgraded to Hold from Buy at Pareto
Pareto downgraded Swedish Orphan Biovitrum (BIOVF) to Hold from Buy with a SEK 470 price target The firm cites valuation following the stock’s recent rally for the downgrade. Published first…
Swedish Orphan Biovitrum initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Swedish Orphan Biovitrum (BIOVF) with a Buy rating and SEK 530 price target Sobi is a profitable, cash-generative rare-disease biopharma c...
Swedish Orphan Biovitrum AB Earnings Call Transcript: Q1 2026
Q1 2026 saw 24% revenue growth and a 38% adjusted EBITDA margin, driven by strong launches and portfolio expansion. Key products like ALTUVOCT, Gamifant, Aspaveli, and Doptelet delivered robust growth, and the outlook for 2026 remains positive with continued investment in launches and R&D.
Swedish Orphan Biovitrum AB Quarterly report: Q1 2026
Swedish Orphan Biovitrum AB has published its Q1 2026 quarterly earnings report on April 28, 2026.
Swedish Orphan Biovitrum AB Slides: Q1 2026
Swedish Orphan Biovitrum AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, March 27, 2026 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be ...
Swedish Orphan Biovitrum AB Slides: Investor presentation
Swedish Orphan Biovitrum AB has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.
Swedish Orphan Biovitrum price target raised to SEK 470 from SEK 395 at Barclays
Barclays analyst Shirley Chen raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 470 from SEK 395 and keeps an Overweight rating on the shares. Published first…
Swedish Orphan Biovitrum price target raised to SEK 500 from SEK 470 at Berenberg
Berenberg analyst Harry Gillis raised the firm’s price target on Swedish Orphan Biovitrum (BIOVF) to SEK 500 from SEK 470 and keeps a Buy rating on the shares. Published first…
Swedish Orphan Biovitrum downgraded to Hold from Buy at Danske Bank
Danske Bank downgraded Swedish Orphan Biovitrum (BIOVF) to Hold from Buy.
Swedish Orphan Biovitrum AB Transcript: CMD 2026
Ambitious plans target doubling revenue to SEK 55 billion by 2030, driven by six major product launches and global expansion. Robust R&D, digital innovation, and disciplined financial management underpin growth, with a focus on rare diseases and new therapeutic areas.
Swedish Orphan Biovitrum AB Press release: FY 2026
Swedish Orphan Biovitrum AB issued a press release on February 18, 2026, disclosing material business information to investors.